If you have ulcerative colitis and your gastroenterologist has prescribed Omvoh, the most pressing question is whether Cigna will pay for it. The short answer is that Cigna does cover Omvoh for ulcerative colitis, but coverage is conditional. It is gated behind prior authorization, and for many plans it is gated behind step therapy, meaning you may have to document that you tried other treatments first. Cigna publishes its own coverage policies for Omvoh, so the rules are not a mystery. Understanding how Cigna handles this specific drug, what its policy asks for, and how to verify your own plan can be the difference between a clean approval and a frustrating denial.
What Omvoh Is and Why Coverage Has Conditions
Omvoh, the brand name for mirikizumab-mrkz, is an interleukin-23 antagonist that selectively binds the p19 subunit of IL-23 and blocks its interaction with the IL-23 receptor, according to the FDA prescribing information on DailyMed. The FDA first approved it for moderately to severely active ulcerative colitis in adults in 2023. Its support comes from the phase 3 LUCENT trials published in the New England Journal of Medicine, where clinical remission at week 12 reached 24.2 percent on mirikizumab versus 13.3 percent on placebo, and at week 40 reached 49.9 percent versus 25.1 percent. Because it is a high-cost specialty biologic, insurers including Cigna apply utilization management to confirm the drug is being used appropriately before they agree to pay.
How Cigna Administers Omvoh Coverage
Cigna manages its pharmacy benefit through Express Scripts, its pharmacy benefit manager, and dispenses specialty biologics like Omvoh through Accredo, its specialty pharmacy. Omvoh is unusual because it uses two routes of administration. The FDA label specifies a three-dose intravenous induction of 300 mg at Weeks 0, 4, and 8, followed by subcutaneous maintenance of 200 mg at Week 12 and every 4 weeks thereafter. Cigna mirrors this split with two separate coverage policies, one for the intravenous induction product and one for the subcutaneous maintenance product. Both require prior authorization before benefits apply, so the induction and maintenance phases of your treatment are each reviewed against criteria.
What Cigna's Prior Authorization Typically Requires
Cigna's published coverage policies set out specific conditions that the typical request must satisfy. For ulcerative colitis induction, the intravenous policy approves three induction doses when the patient is 18 or older and the drug is prescribed by or in consultation with a gastroenterologist, with that approval generally running about three months to cover the induction series. For maintenance, the subcutaneous policy typically approves initial therapy for six months when the patient will receive the intravenous induction doses within three months, again under a gastroenterologist. Continuation past the first six months usually requires evidence of benefit.
Cigna accepts objective or symptom-based measures of response, including the following:
Fecal markers such as fecal calprotectin or serum markers such as C-reactive protein
Endoscopic assessment or a reduced corticosteroid dose
Symptom improvement such as decreased rectal bleeding, stool frequency, pain, or fatigue
The Step Therapy Hurdle for Omvoh
Beyond the prior authorization criteria above, many Cigna plans add a step therapy requirement. Cigna's coverage policies note that for Individual and Family Plans, Omvoh requires the use of preferred products before the requested product is approved, directing readers to its separate preferred specialty management policy. That policy requires documented trials of preferred products, when clinically appropriate, before a non-preferred product is approved. Whether step therapy applies to you, and which agents count as preferred, depends on your specific plan and formulary, and these placements change over time. The clinical backdrop matters here. The AGA living guideline on moderate-to-severe ulcerative colitis recommends advanced therapies including IL-23 inhibitors and favors early use of higher-efficacy medications, which can support a request when prior agents have failed.
How to Verify Your Own Plan and Prepare
Because Cigna's standard coverage policies can differ from your specific benefit plan, the policies themselves state that your individual plan document always supersedes the general policy. The most reliable way to confirm coverage is to read your own plan. Log in to your Cigna member portal or call the number on your insurance card to confirm whether Omvoh is on your formulary, what tier it sits on, and whether step therapy applies to your plan. Ask Express Scripts or Accredo to confirm prior authorization status, and ask your gastroenterology office to submit the authorization with your treatment history attached. The stronger your documentation of disease activity and any prior therapies, the smoother the review tends to be.
Conclusion
Cigna does cover Omvoh for ulcerative colitis, but that coverage runs through prior authorization on both the intravenous induction and subcutaneous maintenance products, and frequently through step therapy on Individual and Family Plans. The approval criteria in Cigna's own published policies are concrete and meetable: a gastroenterologist prescriber, an appropriate diagnosis, and, for continuation, documented evidence that the drug is working. None of these conditions guarantee a particular copay or tier, and your individual plan document is the final word. By reading your plan, confirming whether preferred products must be tried first, and assembling a clear record of your ulcerative colitis history and treatment response, you give your gastroenterology team the material they need to build an authorization request that meets Cigna's requirements from the start.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.